Testing the drug Keynatinib in B-cell lymphoma that came back
Original title: Phase Ib Clinical Study of Keynatinib
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test of the drug in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a drug called Keynatinib in people whose B-cell lymphoma came back.
Who this trial is for. This trial is for people with B-cell lymphoma that came back or stopped responding to treatment. It tests a drug called Keynatinib. The team also looks at how much of the drug reaches the brain and the fluid around it in people whose lymphoma started in the brain.
Where it stands. This trial has not reported results. It is measuring how well the drug works and how safe it is. The team is also measuring how much of the drug gets into the brain and the fluid around it. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: If this sounds like your situation, you could ask your care team about it. They know your case and can say if it is worth looking into.
What it doesn't mean: A trial is a test, not a proven treatment. Joining one does not promise that it will help you. It is not a cure, and no one can promise you a spot.
Source: ClinicalTrials.gov, October 29, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.